Story
Bayer to Invest $2.2 Billion in Ohio Manufacturing Plant to Boost US Sales
Summary
The German pharmaceutical company announced a major investment in a new New Albany, Ohio, facility, aiming to create 600 permanent jobs and double its U.S. revenue by the end of the decade.
German pharmaceutical giant Bayer announced on Friday a significant $2.2 billion investment to build a new manufacturing facility in New Albany, Ohio, a strategic move aimed at expanding its U.S. production capabilities and increasing revenue from the American market.
Investment and Job Creation
According to the company's statement, the project is expected to create approximately 600 permanent positions in the region. An additional 1,500 temporary jobs are anticipated during the construction phase of the new plant.
The investment underscores Bayer's focus on strengthening its foothold in the lucrative U.S. healthcare market, which is a key component of its global growth strategy.
Boosting U.S. Market Presence
Bayer's pharmaceuticals unit has seen its U.S. share of global revenue grow from 20% in 2018 to 35%, according to Sebastian Guth, the division's chief operating officer. The company has set an ambitious goal to double its U.S. sales by the end of the decade.
AdThis expansion is expected to be supported by several key products in Bayer's portfolio, including:
- Kerendia: A treatment for chronic kidney disease.
- Nubeqa: A drug for prostate cancer.
- Asundexian: An investigational drug candidate designed for stroke prevention.
Industry Context
Bayer's expansion in the U.S. comes against the backdrop of an ongoing debate over prescription drug costs. Prices for medicines in the United States remain substantially higher than in most other developed nations, a persistent focus of political and regulatory attention.
Read next
More on Stocks
Foghorn Therapeutics Stock Extends Decline After Eli Lilly Partnership Ends
Shares of Foghorn Therapeutics plunged for a second day after the company and partner Eli Lilly terminated their collaboration, halting development of a key drug candidate and prompting a wave of analyst downgrades.
Southport Acquisition Corp. II Raises $210 Million in NYSE Debut
The special purpose acquisition company sold 21 million units at $10.00 each, including a partial exercise of the over-allotment option, with proceeds placed in a trust for a future merger.
S&P/TSX Composite Gains Nearly 1% to End Week on Strength in Materials, Tech
Canada's main stock index rose 0.99% on Friday, driven by a broad rally in the Materials, Industrials, and IT sectors. The advance was accompanied by a drop in market volatility, while key commodity prices also ticked higher.
Bovespa Index Surges 2.6% to Three-Month High in Broad-Based Rally
Brazil's benchmark Bovespa stock index closed up 2.63% on Friday, reaching its highest level in three months, driven by strong performance in the real estate and basic materials sectors. However, a rise in the market's volatility index to a three-year high indicated underlying investor caution.